Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
This trial focuses on obesity in adults with type 2 diabetes, addressing the critical question of how retatrutide performs when glycemic control is a co-primary endpoint alongside weight loss
Initial Wegovy Injection Dose Escalation Schedule (all indications) Week 1 to week 4: 0.25mg once a week Week 5 to week 8: 0.5mg once a week Week 9 to week 12: 1mg once a week Week 13 to week 16: 1.7mg once a week Maintenance injection dose guidance Adult weight reduction maintenance dose: 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly
GLP-1 Side Effects Vs Benefits: Should You Be Concerned
Briefly, a RT-PCR-nested amplification was performed, and purified PCR products were quantified using the PicoGreen assay (Invitrogen, Carlsbad, CA, USA), and quality analysed using the BioAnalyzer DNA 1000 LabChip (Agilent, Santa Clara, CA, USA) prior to sequencing
Retatrutide is being developed for both obesity and type 2 diabetes but is not yet licensed for either indication in the UK
